Concepts (87)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Pruritus | 15 | 2020 | 29 | 3.980 |
Why?
|
Dermatology | 5 | 2023 | 69 | 1.150 |
Why?
|
Peripheral Nervous System Diseases | 2 | 2020 | 27 | 0.800 |
Why?
|
Publishing | 3 | 2008 | 89 | 0.710 |
Why?
|
Triamcinolone Acetonide | 1 | 2020 | 13 | 0.700 |
Why?
|
Periodicals as Topic | 3 | 2008 | 172 | 0.650 |
Why?
|
Emollients | 1 | 2013 | 5 | 0.430 |
Why?
|
Histamine Antagonists | 1 | 2013 | 5 | 0.430 |
Why?
|
Terminology as Topic | 2 | 2015 | 138 | 0.340 |
Why?
|
Severity of Illness Index | 2 | 2013 | 1448 | 0.320 |
Why?
|
Editorial Policies | 2 | 2006 | 53 | 0.300 |
Why?
|
Bibliometrics | 2 | 2008 | 27 | 0.300 |
Why?
|
Histamine | 1 | 2005 | 27 | 0.260 |
Why?
|
Medical Records | 1 | 2006 | 137 | 0.260 |
Why?
|
Ice | 1 | 2005 | 5 | 0.250 |
Why?
|
Pruritus Ani | 1 | 2005 | 1 | 0.250 |
Why?
|
Dermatitis, Seborrheic | 1 | 2005 | 6 | 0.250 |
Why?
|
Regional Blood Flow | 1 | 2005 | 107 | 0.250 |
Why?
|
Hot Temperature | 1 | 2005 | 125 | 0.250 |
Why?
|
Humans | 22 | 2023 | 59328 | 0.240 |
Why?
|
Diagnostic Errors | 1 | 2005 | 98 | 0.230 |
Why?
|
Cervical Vertebrae | 2 | 2013 | 100 | 0.220 |
Why?
|
Skin | 1 | 2005 | 351 | 0.210 |
Why?
|
Spinal Diseases | 1 | 2003 | 47 | 0.210 |
Why?
|
Antipruritics | 2 | 2012 | 2 | 0.190 |
Why?
|
Injections, Intralesional | 1 | 2020 | 12 | 0.180 |
Why?
|
Chronic Disease | 4 | 2013 | 732 | 0.180 |
Why?
|
Nervous System Diseases | 2 | 2015 | 95 | 0.170 |
Why?
|
History, Ancient | 1 | 2015 | 11 | 0.120 |
Why?
|
Sunlight | 1 | 2015 | 29 | 0.120 |
Why?
|
History, 19th Century | 1 | 2015 | 42 | 0.120 |
Why?
|
Retrospective Studies | 3 | 2020 | 5975 | 0.110 |
Why?
|
History, 20th Century | 1 | 2015 | 226 | 0.110 |
Why?
|
Mianserin | 1 | 2013 | 3 | 0.110 |
Why?
|
Cyclohexanecarboxylic Acids | 1 | 2013 | 9 | 0.110 |
Why?
|
Antidepressive Agents, Tricyclic | 1 | 2013 | 20 | 0.110 |
Why?
|
Excitatory Amino Acid Antagonists | 1 | 2013 | 31 | 0.110 |
Why?
|
Amines | 1 | 2013 | 30 | 0.110 |
Why?
|
Treatment Outcome | 3 | 2020 | 5142 | 0.110 |
Why?
|
Receptors, Opioid, kappa | 1 | 2012 | 3 | 0.100 |
Why?
|
gamma-Aminobutyric Acid | 1 | 2013 | 79 | 0.100 |
Why?
|
Male | 6 | 2013 | 27509 | 0.100 |
Why?
|
Behavior Therapy | 1 | 2013 | 161 | 0.100 |
Why?
|
Arm | 2 | 2013 | 38 | 0.090 |
Why?
|
Receptors, Opioid, mu | 1 | 2010 | 15 | 0.090 |
Why?
|
Aminoquinolines | 1 | 2009 | 15 | 0.090 |
Why?
|
Fluorouracil | 1 | 2009 | 54 | 0.080 |
Why?
|
Carcinoma, Basal Cell | 1 | 2009 | 61 | 0.080 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2009 | 233 | 0.070 |
Why?
|
Peer Review, Research | 1 | 2008 | 46 | 0.070 |
Why?
|
Psychophysiologic Disorders | 1 | 2007 | 7 | 0.070 |
Why?
|
Skin Pigmentation | 1 | 2006 | 32 | 0.070 |
Why?
|
Skin Diseases | 1 | 2007 | 74 | 0.060 |
Why?
|
Dermatitis, Atopic | 1 | 2005 | 21 | 0.060 |
Why?
|
Cold Temperature | 1 | 2005 | 51 | 0.060 |
Why?
|
Soaps | 1 | 2005 | 6 | 0.060 |
Why?
|
Review Literature as Topic | 1 | 2005 | 33 | 0.060 |
Why?
|
Decision Trees | 1 | 2005 | 50 | 0.060 |
Why?
|
Female | 5 | 2013 | 30827 | 0.060 |
Why?
|
Skin Neoplasms | 1 | 2009 | 404 | 0.060 |
Why?
|
Middle Aged | 3 | 2013 | 16238 | 0.060 |
Why?
|
Antineoplastic Agents | 1 | 2009 | 643 | 0.060 |
Why?
|
Peer Review | 1 | 2004 | 25 | 0.060 |
Why?
|
Uncertainty | 1 | 2023 | 32 | 0.050 |
Why?
|
Biopsy | 1 | 2005 | 373 | 0.050 |
Why?
|
Pain | 1 | 2005 | 406 | 0.050 |
Why?
|
United States | 2 | 2006 | 7494 | 0.050 |
Why?
|
Aged | 3 | 2013 | 13293 | 0.050 |
Why?
|
Radiography | 1 | 2003 | 505 | 0.050 |
Why?
|
Reproducibility of Results | 1 | 2005 | 1549 | 0.050 |
Why?
|
Time Factors | 1 | 2004 | 3567 | 0.030 |
Why?
|
Spinal Nerves | 1 | 2013 | 5 | 0.030 |
Why?
|
Morphinans | 1 | 2012 | 1 | 0.030 |
Why?
|
Butorphanol | 1 | 2012 | 4 | 0.030 |
Why?
|
Spiro Compounds | 1 | 2012 | 12 | 0.030 |
Why?
|
Metabolic Clearance Rate | 1 | 2009 | 42 | 0.020 |
Why?
|
Administration, Topical | 1 | 2009 | 52 | 0.020 |
Why?
|
Naloxone | 1 | 2010 | 54 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2010 | 281 | 0.020 |
Why?
|
Naltrexone | 1 | 2010 | 76 | 0.020 |
Why?
|
Administration, Oral | 1 | 2010 | 345 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2010 | 810 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2010 | 666 | 0.020 |
Why?
|
Adult | 1 | 2003 | 15735 | 0.020 |
Why?
|
Follow-Up Studies | 1 | 2010 | 2323 | 0.010 |
Why?
|
Risk Assessment | 1 | 2010 | 1907 | 0.010 |
Why?
|
Animals | 1 | 2012 | 19612 | 0.010 |
Why?
|